Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONStandard

ALVESCO

CICLESONIDE

Standard Dose
0.08MG/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ALVESCO is listed in Drugs@FDA under application 021658 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength AEROSOL, METERED;INHALATION - 0.08MG/INH Sponsor COVIS Submission history Latest submission status date: 2023-02-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALVESCO is listed in Drugs@FDA under application 021658 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength AEROSOL, METERED;INHALATION - 0.08MG/INH Sponsor COVIS Submission history Latest submission status date: 2023-02-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.